RT Journal Article
SR Electronic
T1 A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.01.21261297
DO 10.1101/2021.08.01.21261297
A1 Sheikh-Mohamed, Salma
A1 Isho, Baweleta
A1 Chao, Gary Y.C.
A1 Zuo, Michelle
A1 Nahass, George R.
A1 Salomon-Shulman, Rachel E.
A1 Blacker, Grace
A1 Fazel-Zarandi, Mahya
A1 Rathod, Bhavisha
A1 Colwill, Karen
A1 Jamal, Alainna
A1 Li, Zhijie
A1 de Launay, Keelia Quin
A1 Takaoka, Alyson
A1 Garnham-Takaoka, Julia
A1 Fahim, Christina
A1 Paterson, Aimee
A1 Li, Angel Xinliu
A1 Haq, Nazrana
A1 Barati, Shiva
A1 Gilbert, Lois
A1 Green, Karen
A1 Mozafarihashjin, Mohammad
A1 Samaan, Philip
A1 Budylowski, Patrick
A1 Siqueira, Walter L.
A1 Mubareka, Samira
A1 Ostrowski, Mario
A1 Rini, James M.
A1 Rojas, Olga L.
A1 McGeer, Allison
A1 Weissman, Irving L.
A1 Tal, Michal Caspi
A1 Straus, Sharon
A1 Gingras, Anne-Claude
A1 Gommerman, Jennifer L.
YR 2021
UL http://medrxiv.org/content/early/2021/08/19/2021.08.01.21261297.abstract
AB The first line of defense against SARS-CoV-2 is the upper respiratory tract, yet we know little about the amount, type, and kinetics of mucosal anti-Spike antibodies (Ab) in response to intramuscular (i.m.) COVID-19 vaccination. We analyzed salivary Ab against SARS-CoV-2 Spike following mRNA/mRNA and adenovirus (Ad)/mRNA regimes. While anti-Spike/RBD IgG was detected in the saliva and correlated with the systemic response, anti-Spike/RBD IgA associated with the secretory component (sIgA) was also detected, and did not necessarily correlate with serum Ab. Only modest levels of neutralizing capacity were observed in saliva at 2 weeks post-dose 2, and by 6 months, anti-Spike/RBD IgG were greatly diminished. In contrast, low levels of anti-Spike sIgA persisted up to 6 months after dose 2. Our results show that SARS-CoV-2 vaccination induces an IgG response in the saliva that decays over time and an sIgA response that does not necessarily correlate with systemic immunity.One-Sentence Summary Our study delves into how intra-muscular mRNA/mRNA or mRNA/Ad COVID-19 vaccination regimes confer immunity in the oral cavity with important implications for understanding protection against breakthrough infections in healthy vaccinated people.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an Ontario Together province of Ontario grant to JG and ACG and a Foundation grant from the Canadian Institutes of Health Research to JG (Fund #15992). Funding for the LTCH cohort was provided through a Canada COVID-19 Immunity Task force grant (to SS, AM, MO, ACG and JG). Funding for initial development of the assays in the Gingras lab was provided through generous donations from the Royal Bank of Canada (RBC) and the Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by Canada Foundation for Innovation funding, by the Ontarian Government and by Genome Canada and Ontario Genomics (OGI-139).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mount Sinai Hospital Research Ethics Board (REB) granted approval for recruiting staff in long-term care facilities located in the Greater Toronto Area for blood and saliva collection and for conducting serum ELISAs at the Lunenfeld-Tanenbaum Research Institute (study number: 20-0339-E). The University of Toronto REB granted approval for subject recruitment to collect blood and saliva samples and for conducting saliva ELISAs (study number: 23901). The University of Saskatchewan REB granted approval for saliva sample collection during the pre-COVID era (study number: BIO-USask-1579).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be available upon reasonable request.